CLASS ACTION REMINDER: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Lawsuit by December 15, 2025

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for allegedly misleading investors regarding its drug candidate, sonelokimab (SLK), which was claimed to be superior to existing therapies but reportedly lacks demonstrated clinical advantages [3][4]. Company Overview - MoonLake Immunotherapeutics is a biopharmaceutical company based in Zug, Switzerland, focusing on therapies for inflammatory diseases [2]. Legal Action Details - The lawsuit is on behalf of investors who purchased MoonLake shares from March 10, 2024, to September 29, 2025, with a deadline of December 15, 2025, for investors to seek lead plaintiff status [1][2]. - The complaint alleges that MoonLake failed to disclose that SLK targets the same molecules as the FDA-approved drug BIMZELX, undermining claims of its clinical superiority [3]. Clinical Trial Outcome - On September 28, 2025, MoonLake disclosed that SLK did not achieve efficacy comparable to BIMZELX in Phase 3 clinical trials, leading to a significant stock price drop of $55.75 per share, nearly 90% in one trading day [4].